Which company develops and produces Serputinib/Serpatinib?

Selpercatinib is an oral small molecule tyrosine kinase inhibitor (TKI) specifically targeting RET gene fusion or mutation. It is developed and produced by Eli Lilly and Company of the United States. The advent of this drug marks a new stage in precision treatment of RET targets. As a world-renowned multinational pharmaceutical company, Eli Lilly and Company is headquartered in the United States and has strong R&D and commercialization capabilities in the field of anti-tumor drugs.

Selpercatinib first received breakthrough therapy designation from the FDA in the United States in 2019, and was first approved for marketing under the trade name RETEVMO in 2020 for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC), RET fusion-positive thyroid cancer, and RET-mutated medullary thyroid cancer (MTC).

Compared with traditional chemotherapy, the drug design of cepotinib reflects higher target selectivity and can effectively inhibit RET fusion or mutation-driven signaling pathways while reducing interference with other kinases, thereby reducing non-target toxicity. This high selectivity not only brings better efficacy, but also gives it certain advantages in terms of safety. Eli Lilly provides production and quality assurance for this drug globally. The production base complies with international good manufacturing practices (cGMP) and implements strict control over raw material sources, quality testing, batch tracking and other aspects to ensure the stability and consistency of the drug.

In China, Seputinib has been introduced by Eli Lilly China and approved for marketing. The main dosage form is capsule oral preparation. Although it has been on the market for a short time, in the field of RET-targeted therapy, it has become one of the important options preferred by doctors for RET-positive patients. In the future, with the expansion of more indications, advancement of medical insurance negotiations, and popularization of RET testing, seputinib is expected to occupy an even more important position in precision tumor treatment globally and in China.

Reference:https://en.wikipedia.org/wiki/Selpercatinib